Last reviewed · How we verify
Interleukin 2
Interleukin-2 (IL-2) is a cytokine that activates and proliferates T cells and natural killer cells to enhance immune response against cancer and infections.
Interleukin-2 (IL-2) is a cytokine that activates and proliferates T cells and natural killer cells to enhance immune response against cancer and infections. Used for Metastatic renal cell carcinoma, Metastatic melanoma.
At a glance
| Generic name | Interleukin 2 |
|---|---|
| Also known as | IL-2, Aldesleukin; IL-2 or Proleukin®, IL2, Proleukin, Interleukin-2 |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Cytokine immunotherapy |
| Target | IL-2 receptor (CD25) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
IL-2 binds to the IL-2 receptor on lymphocytes, triggering T cell activation, expansion, and differentiation into effector and memory cells. It also enhances natural killer cell activity and promotes immune-mediated tumor destruction. This mechanism leverages the body's own immune system to target malignant cells.
Approved indications
- Metastatic renal cell carcinoma
- Metastatic melanoma
Common side effects
- Capillary leak syndrome
- Hypotension
- Fever
- Chills
- Fatigue
- Nausea
- Thrombocytopenia
- Oliguria/acute kidney injury
Key clinical trials
- Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (PHASE1, PHASE2)
- Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma (PHASE1)
- Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors (PHASE1)
- Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma (PHASE2)
- Neutralizing Interleukin (IL)-6 (PHASE2)
- KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors (PHASE1)
- TREg Activation in the Treatment of the PELADE (Alopecia Areata) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |